𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Safety profile of belimumab: pooled data from placebo-controlled phase 2 and 3 studies in patients with systemic lupus erythematosus

✍ Scribed by Wallace, D.; Navarra, S.; Petri, M.; Gallacher, A.; Thomas, M.; Furie, R.; Levy, R.; van Vollenhoven, R.; Cooper, S.; Zhong, Z.; Freimuth, W.; Cervera, R.

Book ID
118263328
Publisher
SAGE Publications
Year
2012
Tongue
English
Weight
138 KB
Volume
22
Category
Article
ISSN
0961-2033

No coin nor oath required. For personal study only.

πŸ“œ SIMILAR VOLUMES

A phase II, randomized, double-blind, pl
A phase II, randomized, double-blind, placebo-controlled, dose-ranging study of belimumab in patients with active systemic lupus erythematosus
✍ Wallace, Daniel J. ;Stohl, William ;Furie, Richard A. ;Lisse, Jeffrey R. ;McKay, πŸ“‚ Article πŸ“… 2009 πŸ› John Wiley and Sons 🌐 English βš– 372 KB πŸ‘ 2 views

## Abstract ## Objective To assess the safety, tolerability, biologic activity, and efficacy of belimumab in combination with standard of care therapy (SOC) in patients with active systemic lupus erythematosus (SLE). ## Methods Patients with a Safety of Estrogens in Lupus Erythematosus: National

Pharmacokinetics, tolerability, and prel
Pharmacokinetics, tolerability, and preliminary efficacy of paquinimod (ABR-215757), a new quinoline-3-carboxamide derivative: Studies in lupus-prone mice and a multicenter, randomized, double-blind, placebo-controlled, repeat-dose, dose-ranging study in patients with systemic lupus erythematosus
✍ Anders A. Bengtsson; Gunnar Sturfelt; Christian Lood; Lars RΓΆnnblom; Ronald F. v πŸ“‚ Article πŸ“… 2012 πŸ› John Wiley and Sons 🌐 English βš– 215 KB